GSK PLC (GSK)
34.39
-0.72
(-2.05%)
USD |
NYSE |
Nov 14, 16:00
34.52
+0.13
(+0.38%)
After-Hours: 20:00
GSK Research and Development Expense (Quarterly): 1.898B for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.898B |
| June 30, 2024 | 1.864B |
| March 31, 2024 | 1.819B |
| December 31, 2023 | 2.542B |
| September 30, 2023 | 1.994B |
| June 30, 2023 | 1.678B |
| March 31, 2023 | 1.532B |
| December 31, 2022 | 2.113B |
| September 30, 2022 | 1.584B |
| June 30, 2022 | 1.561B |
| March 31, 2022 | 1.480B |
| December 31, 2021 | 1.855B |
| September 30, 2021 | 1.952B |
| June 30, 2021 | 1.631B |
| March 31, 2021 | 1.541B |
| December 31, 2020 | 1.537B |
| September 30, 2020 | 1.473B |
| June 30, 2020 | 1.613B |
| March 31, 2020 | 1.521B |
| December 31, 2019 | 1.601B |
| September 30, 2019 | 1.486B |
| June 30, 2019 | 1.430B |
| March 31, 2019 | 1.311B |
| December 31, 2018 | 1.384B |
| September 30, 2018 | 1.287B |
| Date | Value |
|---|---|
| June 30, 2018 | 1.261B |
| March 31, 2018 | 1.257B |
| December 31, 2017 | 1.605B |
| September 30, 2017 | 1.371B |
| June 30, 2017 | 1.611B |
| March 31, 2017 | 1.189B |
| December 31, 2016 | 1.246B |
| September 30, 2016 | 1.211B |
| June 30, 2016 | 1.276B |
| March 31, 2016 | 1.167B |
| December 31, 2015 | 1.599B |
| September 30, 2015 | 1.281B |
| June 30, 2015 | 1.244B |
| March 31, 2015 | 1.314B |
| December 31, 2014 | 1.549B |
| September 30, 2014 | 1.341B |
| June 30, 2014 | 1.361B |
| March 31, 2014 | 1.421B |
| December 31, 2013 | 1.732B |
| September 30, 2013 | 1.396B |
| June 30, 2013 | 1.611B |
| March 31, 2013 | 1.404B |
| December 31, 2012 | 1.836B |
| September 30, 2012 | 1.480B |
| June 30, 2012 | 1.463B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.473B
Minimum
Sep 2020
2.542B
Maximum
Dec 2023
1.740B
Average
1.622B
Median
Research and Development Expense (Quarterly) Benchmarks
| AstraZeneca PLC | 3.008B |
| Pfizer Inc | 2.598B |
| Autolus Therapeutics PLC | 36.61M |
| Moderna Inc | 1.137B |
| Biodexa Pharmaceuticals PLC | -- |